The JP Morgan lady in their promo video says that investors are looking for companies that have long patent dates , with novel treatments in areas with low competition , and with a clear pipeline to profit .
This event sometimes opens with a big blockbuster deal announcement ( lacking in last 2 years ) , but is the place where many licensing and partner deals are announced .
You are in the heart of the pharma investing world - where better place to showcase your new partner ?
Faron just announced they will be at the JP Morgan Healthcare Conference in San Fransisco next week .
This is a major event , lots of meetings , and quite often deals are done and signed .
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
https://twitter.com/FaronPharm/status/1610999243526782976?s=20&t=Dxmq8C3kuQ5cd-JgXmzxDQ
Markku was pressed on this issue at the last interview , and we had a long discussion regarding his confidence on the matter . Based on what he knew at the time - funding was not an 'issue' .
From which we could take it that he had options on the table .
In normal years , I may have taken that with the usual pinch of salt , as we have become used to the endless placing RNS's .
But with the BEXMAB results being so astoundingly good , and the Matins P2 dosing/biomarker package finally all done and presented to FDA , Faron are at last in a position to do a 'proper' deal .
Up until now , there were loose ends that needed to be finalised ( such as the dosing/soluble clever1 issue)
The picture just wasn't clear enough.
In my opinion they now have pretty much enough of the jigsaw put together that it meets the criteria of interested parties , who would not want to take on a 'half finished' study .
Firing up BEXMAB in such a short time was a gamble , especially while they were still working on MATINS , but boy has that paid off .
I'm excited to see what comes next.
Lets hope the interest builds .
Nice start to the year .
The Finnish company's "miracle drug" produced revolutionary results - the patient's cancer was completely cured.
The new results are amazing
Newly released results show that the first patient to come to treatment, who had a previously reported partial response, has continued to gain strength.
After four cycles of treatment, the cancer cells in the bloodstream and bone marrow had disappeared and the blood count had returned to normal, meaning the patient had a complete response and the cancer was cured.
Well the Christie in Manchester is one of the trial sites for MATINS .
Not us specifically as we aren't approved , but shows that we are a. in the right place , b. being watched by the right people , and c. are front and centre part of the future of cancer treatment .
The company only has an Mcap of £35m .
Hasn't even started getting going .
2023 will be transformational .
Investors don't give a hoot , they know whats coming .
Traders however will have a busy morning chasing this around .
I may buy some more - good luck
Must admit I didn't expect to be topping up again today , but 58p is frankly ridiculous .
That's about what I paid about a year ago - with about 8 months to wait for approval ( and not even certainty about that )
Oh well , shouldn't complain .
Got a nice pile now , so will sit back and see how they get on in 2023 .
Merry Christmas all , hope everyone had a nice break , and wishing you all a Happy New Year too .
News just breaking from LLS about another of their supported therapies getting FDA approval .
Friends in high places ;-)
LLS support contributed directly to this approval, with grants and scholar awards to several researchers working on this important immunotherapy.
https://www.lls.org/news/fda-approves-first-class-bispecific-antibody-treatment-follicular-lymphoma?utm_source=Twitter&utm_medium=Social&utm_campaign=12-27-2022-FDA-Approval-Bispecific-Antibody-Treatment-Follicular-Lymphoma-ZGM
Great news ! . Must admit I was starting to think it may never come .
This should get 2023 off to a flying start .
Merry Christmas all .
Can someone tell me that this is not massive news ?
Only 13% of CPI treatments are currently responsive .
Bex aims to increase that number significantly , by igniting the immune system .
Not only that , but after a short treatment with Bex , they can tell what CPI you are likely or not likely to respond to ( if treated with Bex in combination )
Essentially a fine tuning diagnostic tool that can be deployed to eliminate pointless CPI treatments when the patient would never respond , and selecting one that does .
Round peg in a round hole .
We hear of these developments way after they are actually made . Makes you wonder what else they know that is yet to be revealed .
These patents just keep rolling in .
If you can take the time to read the paragraphs below , it explains that with this discovery , they now have another biomarker for Bex that actually selects what combi treatment the patient is best suited to !!
No wonder the Bexcombo trial has been offered first line patients .
It just keeps getting better !
Now we have -
ANTI-CLEVER-1 AGENTS FOR CONTROLLING THE EXPRESSION OF CELL SURFACE MARKERS ON LEUCOCYTES, AND USING THESE TO GUIDE ANTI-CLEVER-1 BASED CANCER TREATMENT.
The present invention relates to monitoring expression levels of one or more cell surface marker in circulating T cell populations in relation to anti-Clever-1 treatment and choosing the best combination agent to initiate treatment together with anti-Clever-1 therapy after the observed changes in the expression of one or more cell surface marker.
By monitoring the change in these commonly known checkpoint molecules during anti-Clever-1 treatment, we can pick a checkpoint inhibitor that should be given in combination with the on-going anti-Clever-1 treatment. If a certain checkpoint molecule does not react to anti-Clever-1 treatment in the wanted way, then a specific checkpoint inhibitor targeting the wanted checkpoint molecule is administered in combination with to the on-going anti-Clever-1 treatment. The expression of cell surface markers can be used to guide anti-Clever-1 treatment or the best possible checkpoint inhibitor(s) combination treatment with anti-Clever-1 therapy.
he present invention also provides a novel biomarker-based combination treatment for cancer patients and thus reduce or even eliminate the abovementioned problems in defining non-responders from responding patients. The present invention gives the possibility of probing the molecular landscape of solid tumors via a blood draw to define changes in the patient during anti-Clever-1 therapy and subsequently gives the opportunity to select the best possible check-point inhibition combination treatment with anti-Clever-1 therapy.
https://patents.justia.com/patent/20220404366
I think we may look back next year and see the pivotal moment for Faron was when they gained the support of the LLS .
Not only did it raise the profile of Bexmab , but it allowed Faron a seat on the train that gets you to market if you have success .
Having a great trial result is one thing , but if you are not connected to the right mechanism to convert that into a commercial product , you are still in limbo .
Take this tweet today from LSS -
https://twitter.com/LLSusa/status/1605937993424027651?s=20&t=LwY_m0kRHIfrnHy5OEabiQ
They are actively seeking donations and support themselves , but justify their position as they are the most credible party out there who can seek out , support and finance new treatments to the point of approval .
In the last 5 years - 3 out of 4 of every blood cancers treatments approved by the FDA were supported by the LSS .
Only got a small holding here , but I just doubled it .
Merry Christmas all , see what comes in the next week or so .
I guess it's to keep the story out there for those that have yet to discover Faron ( which is 99.9% of the world by my reckoning )
Big Pharma have their own intel I'm sure , but it helps to lay the progress out there for non scientific analysts to look at .
I appreciate that in the past when he was pressed on the issue of finance , he brushed it off with ' we have options ' , and then the IPF Partners funding appeared , along with further placings , but I really think that we have arrived at a point where there really are 'proper' options , ie Partners .
We now have the Bexmab P1 data showing a potential breakthrough therapy ( on top of the all the other Bex data )
Every bit of news takes us closer to being a marketable therapy .
We now appear to be on the panel of the worlds most prestigious Leukemia research organisations latest podcast , following the publication of that Bexmab patient data .
I think we have the ear of the big players , and being still 100% wholly owned , will surely be in the position of having propositions put infront of us .
Bristol Myers Squibb , being a co partner of LSS , must surely have first movers advantage here , as they are closer than any of the other majors , and it would be a feather in their cap , along with LSS , to have their names associated with another product brought to market in the Hematology world , their latest big investment area .
But then we have the Matins pivotal trial plans , along with other combi trials planned .
A lot of funding options .
Faron needs partners , but then these majors need future drugs.
It just takes one arm of Bex to get cashflow , and we are up and away .
Or following the Matins P2 determination , someone decides they better move and have the lot .
Either way , I just have to trust that the BOD are up to the job. And in my opinion , with the investment the Jalkanens have involved , both financially , and in career and reputation , along with Toni , MLF , and all the team that has been built up in the last year or so , we have never been in a better position to make that next step up to being a revenue generating company.
Hear from LLS TAP staff and TAP European biotech partners who are dreaming big and making bold progress for blood cancer patients.
https://www.youtube.com/watch?v=u9mu95uZapU&t=2s
Of course we are already part of the TAP program .
https://www.lls.org/therapy-acceleration-program-portfolio
Great to see Faron being part of this .
The next key player to get further funding ?
New event in the new year -
MLF on the panel for discussion
https://twitter.com/FaronPharm/status/1605600209655910401?s=20&t=MJg3V2GY7jQRA7Ux12KYtA
https://na.eventscloud.com/website/49472/welcome/
This TAP looks interesting -
https://na.eventscloud.com/website/49472/about-tap/